期刊文献+

卡托普利生物黏附型缓释胶囊大鼠体内药动学研究 被引量:1

Pharmacokinetic Study of Captopril/Bioadhesive Sustained-Release Capsules in Rats
下载PDF
导出
摘要 研究卡托普利生物黏附型缓释胶囊(Captopril/bioadhesive sustained-release capsules,CBSRCs)在大鼠体内的药动学,通过建立高效液相色谱(HPLC)-紫外检测法测定卡托普利(Captopril,Cap)的血药浓度,研究了大鼠灌胃CBSRCs和卡托普利普通片(Captopril ordinary tablet,COT)各5 mg/kg后16 h内的药动学,DAS 2.0软件计算出相应的药动学参数,t检验比较两种制剂的药动学参数。结果表明,Cap浓度在12.5~800μg/L范围内线性关系良好(r=0.998 7),最低检测限为12.5μg/L,平均回收率为99.40%,平均日内RSD为3.97%,平均日间RSD为4.84%;单剂量口服CBSRCs和COT,Tmax分别为(3.12±0.67),(1.53±0.27)h;Cmax为(722.97±133.68),(1 114.47±208.36)μg/L;T1/2α为(1.88±0.38),(1.15±0.21)h;T1/2β为(3.76±0.75),(2.87±0.59)h;CL为(2.87±0.51),(3.43±0.67)L/h,Vd为(10.98±1.90),(13.21±2.57)L;AUC0-t为(4 856.03±835.46),(4 616.29±915.49)μg.h/L;AUC0-∞为(5 218.39±1 037.58),(4 705.83±894.56)μg.h/L。CBSRCs和COT相比,T1/2α,T1/2β,AUC0-t,AUC0-∞,CL,Vd,Tmax,Cmax差异显著(P<0.05或0.01)。说明CBSRCs与市售COT在大鼠体内的药动学特征差异具有显著性,说明高效液相色谱-紫外检测器测定Cap含量的方法稳定,结果准确可靠。CBSRCs与市售COT相比,CBSRCs显著改善了卡托普利原药的药动学性质,具有缓释和长效的作用。 For the purpose of investigating the pharmacokinetics of captopril/bioadhesive sustained-re-lease capsules(CBSRCs),An HPLC process with UV detection was established for the determination of plasma concentration of captopril in rats.After CBSRCs and Captopril ordinary tablet(COT) were orally administrated to rats at a single dosage of 5 mg/kg respectively,their pharmacokinetic behaviors in 16 h were examined.The pharmacokinetics parameters were calculated and analyzed by DAS 2.0 software.Linear calibration curves of Cap were described as follows:Y=0.006 5x-0.038 2,r=0.998 7.Minimum detectable concentration was 12.5μg/L.Mean recovery was 99.40% for both Cap and internal standard.The variation of recovery between different concentrations of Cap and internal standard was both5%(n =7).Mean relative standard deviation(interday) was 3.97%(n=7).Mean relative standard deviation(day to day) was 4.84%(n= 7).The major pharmacokinetics parameters of CBSRCs and COT were shown as follows: Tmaxwere(3.12±0.67) and(1.53±0.27) h,respectively;Cmaxwere(722.97±133.68) and(111 4.47±208.36)μg/L,respectively;T1/2αwere(1.88±0.38) and(1.15±0.21) h,respectively;T1/2βwere(3.76±0.75) and(2.87±0.59) h,respectively;CL were(2.87±0.51) and(3.43±0.67) L/h,respectively,Vdwere(10.98±1.90) and(13.21±2.57) L,respectively;AUC0-twere(4 856.03±835.46) and(4 616.29±915.49)μg.h/L,respectively;and AUC0-∞were(5 218.39±1 037.58) and(4 705.83 ±894.56)μg.h/L respectively.The T1/2α,T1/2β,AUC0-t,AUC0-∞,CL,Vd,Tmaxand Cmaxof CBSRCs were all significantly different repectively from those of COT(P0.05 or 0.01).The results showed that the process of determination with HPLC was stable and reliable results can be obtained.CBSRCs showed the characteristics of sustained-release and higher efficiency compared with COT.
出处 《中国海洋大学学报(自然科学版)》 CAS CSCD 北大核心 2010年第4期26-30,共5页 Periodical of Ocean University of China
基金 国家自然科学基金项目(30471317)资助
关键词 卡托普利 生物黏附型缓释胶囊 药代动力学 高效液相色谱 captorpril bioadhesive sustained-release capsules pharmacokinetics HPLC
  • 相关文献

参考文献7

  • 1Romankiewjcz J A,Brogden R N,Heel R C,et al.Captopril:an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure[J].Drugs,1983,25(1):6-40.
  • 2田维荣,高申,王世祥.卡托普利在正常人体内的药动学研究[J].中国医院药学杂志,1993,13(2):55-56. 被引量:9
  • 3Seta Y,Higuchi F,Kawahara Y,et al.Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties[J].Int J Pharm,1988a,41:245-254.
  • 4Anaizi N H,Swenson C.Instability of captopril solution[J].Am J Hosp Pharm,1993,50:486-488.
  • 5宋益民,陈西广,唐学玺,刘成圣,孟祥红,刘晨光,贺君,于乐军.卡托普利生物粘附型缓释胶囊的制备及性能[J].中国海洋大学学报(自然科学版),2006,36(3):415-420. 被引量:5
  • 6Kawahara Y,Hisaoka M,Yamazaki Y,et al.Determination of captopril in blood and urine by high-performance liquid chromatography[J].Chem Pharm Bull,1981,29(1):150-157.
  • 7Jankowski A,Skorek A.Captopril:determination in blood and and pharmacokinetics after single oral dose[J].Pharm Biomed Analy,1995,13:655-660.

二级参考文献14

  • 1田维荣,高申,王世祥.卡托普利在正常人体内的药动学研究[J].中国医院药学杂志,1993,13(2):55-56. 被引量:9
  • 2宋益民,陈西广,唐学玺,刘成圣,孟祥红,于乐军.卡托普利/壳聚糖-明胶网络多聚物缓释微球制备工艺的研究[J].海洋水产研究,2005,26(2):53-58. 被引量:2
  • 3王亚敏,石庭森.微球制剂药物控释研究进展[J].中国药学杂志,1996,31(3):131-134. 被引量:17
  • 4Romankiewjcz J A,Brogden R N,Heel R C,et al.Captopril:an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure[J].Drugs,1983,25(1):6-40.
  • 5Guittard G V,Carpenter H A,Quan E S,et al.Dosage form for delivering drug in short period[P].US patent 5178867,1998.
  • 6Wilding I R,Davis S S,Bakhshaee M,et al.Gastrointestinal transit and systemic absorption of Captopril from a pulsed-release formulation[J].Pharm Res,1992,9(5):654-657.
  • 7Deasy P B,Brophy M R,Ecanow B,et al.Effect of ethyl cellulose grade and sealant treatments on the production and in vitro release of microenCapsulated sodium salicylate[J].J Pharm Pharmacol,1984,32:15-20.
  • 8Abubakr O N,Zhang J S.Recent progress in sustained/controlled oral delivery of Captopril:an overview[J].Int J Pharma,2000,194:139-146.
  • 9陈西广,宋益民,唐学玺,等.一种卡托普利复合几丁聚糖缓释微球的制备方法[P].China Pat,200410035433.7,2004-07-28.
  • 10Gallo J M,Hung C T,Perrier D G.Analysis of albumin microsphere preparation[J].Int J Pharm,1984,22:63-66.

共引文献12

同被引文献12

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部